Jiangsu GDK Biotechnology Co Ltd (SHG:688670) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangsu GDK Biotechnology Co Ltd (688670)
Jiangsu GDK Biotechnology Co Ltd (SHG:688670) has a market capitalization of $342.53 Million (CN¥2.34 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #14348 globally and #4316 in its home market, demonstrating a 6.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu GDK Biotechnology Co Ltd's stock price CN¥19.00 by its total outstanding shares 123200000 (123.20 Million). Also see 688670 total assets for a full breakdown of the balance sheet.
Jiangsu GDK Biotechnology Co Ltd Market Cap History: 2021 to 2026
Jiangsu GDK Biotechnology Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $952.52 Million to $342.53 Million (-19.48% CAGR). Also see cash flow conversion of Jiangsu GDK Biotechnology Co Ltd for how efficiently the company converts equity into cash flow.
Jiangsu GDK Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu GDK Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Jiangsu GDK Biotechnology Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.22x
Jiangsu GDK Biotechnology Co Ltd's market cap is 3.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $952.52 Million | $392.27 Million | $82.46 Million | 2.43x | 11.55x |
| 2022 | $551.32 Million | $318.49 Million | $41.54 Million | 1.73x | 13.27x |
| 2023 | $513.08 Million | $134.59 Million | -$70.99 Million | 3.81x | N/A |
| 2024 | $218.50 Million | $80.80 Million | -$93.50 Million | 2.70x | N/A |
| 2025 | $364.71 Million | $113.23 Million | -$173.47 Million | 3.22x | N/A |
Competitor Companies of 688670 by Market Capitalization
Companies near Jiangsu GDK Biotechnology Co Ltd in the global market cap rankings as of September 24, 2026. Review 688670 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Jiangsu GDK Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Jiangsu GDK Biotechnology Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Jiangsu GDK Biotechnology Co Ltd's market cap moved from $952.52 Million to $ 342.53 Million, with a yearly change of -19.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥342.53 Million | -6.08% |
| 2025 | CN¥364.71 Million | +66.91% |
| 2024 | CN¥218.50 Million | -57.41% |
| 2023 | CN¥513.08 Million | -6.94% |
| 2022 | CN¥551.32 Million | -42.12% |
| 2021 | CN¥952.52 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Jiangsu GDK Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $342.53 Million USD |
| MoneyControl | $342.53 Million USD |
| MarketWatch | $342.53 Million USD |
| marketcap.company | $342.53 Million USD |
| Reuters | $342.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu GDK Biotechnology Co Ltd
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008… Read more